Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2010

01-10-2010 | Case Report

Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis

Authors: Takeshi Yamamoto, Jun Matsuda, Hiroyuki Kadoya, Tomoko Namba, Masanobu Takeji, Atsushi Yamauchi

Published in: Clinical and Experimental Nephrology | Issue 5/2010

Login to get access

Abstract

A 76-year-old man developed fever and appetite loss, and then was referred to our hospital because of rapidly progressive renal insufficiency; his serum creatinine increased from 1.2 to 5.9 mg/dl within 1 month. On admission, his blood pressure was 166/92 mmHg, and laboratory findings showed signs of inflammation, anemia, proteinuria, and hematuria. Chest computed tomography (CT) suggested interstitial pneumonia, while a renal biopsy revealed that small arteries and arterioles were affected, and there was pauci-immune glomerulonephritis with cellular and fibrocellular crescents. In addition, an increased myeloperoxidase antineutrophil cytoplasmic antibody titer confirmed microscopic polyangiitis. Treatment with oral prednisolone was initiated and seemed to successfully resolve the vasculitis activity. On the 11th day of admission, a calcium channel blocker, azelnidipine, was added to treat hypertension. Two days later, the patient developed abdominal distension, and abdominal CT showed massive ascites. The ascitic fluid was a milky white transudate with a normal leukocyte count. Neither clinical manifestations nor laboratory findings suggestive of liver cirrhosis, malignancy, infectious peritonitis, or bowel perforation were observed. On the 18th day of admission, azelnidipine was discontinued in view of reports of calcium channel blocker-induced chyloperitoneum in patients undergoing peritoneal dialysis. Immediately, the abdominal distension disappeared, and the ascites appeared to decrease. Azelnidipine appears to have been responsible for the chyloperitoneum. Since a few cases of secondary vasculitis developing chyloperitoneum have been previously reported, vasculitis may have played a role in the development of chyloperitoneum.
Literature
1.
go back to reference Yoshimoto K, Saima S, Nakamura Y. Manidipine hydrochloride induced peritoneal fluid turbidity in two patients on continuous peritoneal dialysis. J Jpn Soc Dial Ther. 1991;24:1171–3. Yoshimoto K, Saima S, Nakamura Y. Manidipine hydrochloride induced peritoneal fluid turbidity in two patients on continuous peritoneal dialysis. J Jpn Soc Dial Ther. 1991;24:1171–3.
2.
go back to reference Tanabe M, Iwata H, Kinoshita M, Sumiya M, Saima S. Manidipine hydrochloride-induced chyloperitoneum in a patient with systemic lupus erythematosus. Clin Nephrol. 1999;51:195–6.PubMed Tanabe M, Iwata H, Kinoshita M, Sumiya M, Saima S. Manidipine hydrochloride-induced chyloperitoneum in a patient with systemic lupus erythematosus. Clin Nephrol. 1999;51:195–6.PubMed
3.
go back to reference Lee T-H, Lee EY, Cho YS, Yoo B, Moon H-B, Lee C-K. Concurrent occurrence of chylothorax and chylous ascites in a patient with Henoch-Schönlein purpura. Scand J Rheumatol. 2003;32:378–9.CrossRefPubMed Lee T-H, Lee EY, Cho YS, Yoo B, Moon H-B, Lee C-K. Concurrent occurrence of chylothorax and chylous ascites in a patient with Henoch-Schönlein purpura. Scand J Rheumatol. 2003;32:378–9.CrossRefPubMed
4.
go back to reference Abadoğlu O, Osma E, Uçan ES, Cavdar C, Akkoç N, Küpelïoğlu A, Akbaylar H. Behçet’s disease with pulmonary involvement, superior vena cava syndrome, chyloptysis and chylous ascites. Respir Med. 1996;90:429–31.CrossRefPubMed Abadoğlu O, Osma E, Uçan ES, Cavdar C, Akkoç N, Küpelïoğlu A, Akbaylar H. Behçet’s disease with pulmonary involvement, superior vena cava syndrome, chyloptysis and chylous ascites. Respir Med. 1996;90:429–31.CrossRefPubMed
5.
go back to reference Sakai H, Kurokawa K, Koyama A, Arimura Y, Kida H, Shigematsu S, et al. Clinical guideline for rapidly progressive glomerulonephritis in Japan. Jpn J Nephrol. 2002;44:55–82. Sakai H, Kurokawa K, Koyama A, Arimura Y, Kida H, Shigematsu S, et al. Clinical guideline for rapidly progressive glomerulonephritis in Japan. Jpn J Nephrol. 2002;44:55–82.
6.
go back to reference Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed
8.
go back to reference Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215–20.PubMed Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215–20.PubMed
9.
go back to reference Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med. 1982;96:358–64.PubMed Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med. 1982;96:358–64.PubMed
10.
go back to reference Cárdenas A, Chopra S. Chylous ascites. Am J Gastroenterol. 2002;97:1896–900.PubMed Cárdenas A, Chopra S. Chylous ascites. Am J Gastroenterol. 2002;97:1896–900.PubMed
11.
go back to reference Browse NL, Wilson NM, Russo F, al-Hassan H, Allen DR. Aetiology and treatment of chylous ascites. Br J Surg. 1992;79:1145–50.CrossRefPubMed Browse NL, Wilson NM, Russo F, al-Hassan H, Allen DR. Aetiology and treatment of chylous ascites. Br J Surg. 1992;79:1145–50.CrossRefPubMed
12.
go back to reference Pomeranz A, Reichenberg Y, Schurr D, Drukker A. Chyloperitoneum: a rare complication of peritoneal dialysis. Perit Dial Int. 1984;4:35–7. Pomeranz A, Reichenberg Y, Schurr D, Drukker A. Chyloperitoneum: a rare complication of peritoneal dialysis. Perit Dial Int. 1984;4:35–7.
13.
go back to reference Yoshimoto K, Saima S, Nakamura Y, Nakayama M, Kubo H, Kawaguchi Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol. 1998;50:90–3.PubMed Yoshimoto K, Saima S, Nakamura Y, Nakayama M, Kubo H, Kawaguchi Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol. 1998;50:90–3.PubMed
14.
go back to reference Tanaka M, Ito K, Matsushita K, Matsushita K. Calcium channel blocker: azelnidipine induced turbid dialysate in patients undergoing peritoneal dialysis. J Jpn Soc Dial Ther. 2006;39(Suppl 1):1000. Tanaka M, Ito K, Matsushita K, Matsushita K. Calcium channel blocker: azelnidipine induced turbid dialysate in patients undergoing peritoneal dialysis. J Jpn Soc Dial Ther. 2006;39(Suppl 1):1000.
15.
go back to reference Kato A, Hishida A, Nakajima T, Ohtake T, Furuya R, Arai T, et al. Manidipine hydrochloride-induced chyloperitoneum in a patient on continuous ambulatory peritoneal dialysis. J Jpn Soc Dial Ther. 1994;27:1185–8. Kato A, Hishida A, Nakajima T, Ohtake T, Furuya R, Arai T, et al. Manidipine hydrochloride-induced chyloperitoneum in a patient on continuous ambulatory peritoneal dialysis. J Jpn Soc Dial Ther. 1994;27:1185–8.
16.
go back to reference Trost BN, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens. 1987;5:81–104.CrossRef Trost BN, Weidmann P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens. 1987;5:81–104.CrossRef
17.
go back to reference Bailey M, Chapin W, Licht H, Reynolds JC. The effects of vasculitis on the gastrointestinal tract and liver. Gastroenterol Clin N Am. 1998;27:747–82.CrossRef Bailey M, Chapin W, Licht H, Reynolds JC. The effects of vasculitis on the gastrointestinal tract and liver. Gastroenterol Clin N Am. 1998;27:747–82.CrossRef
Metadata
Title
Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis
Authors
Takeshi Yamamoto
Jun Matsuda
Hiroyuki Kadoya
Tomoko Namba
Masanobu Takeji
Atsushi Yamauchi
Publication date
01-10-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0302-3

Other articles of this Issue 5/2010

Clinical and Experimental Nephrology 5/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.